Abstract
Background: Due to the high level of argininosuccinate synthase (ASS), a key enzyme for the formation of arginine from citrulline, human breast cancers are often resistant to arginine deprivation therapy. An antimetabolite, Lcanavanine (L-CAV), can be incorporated into proteins in the place of arginine, disturbing protein conformation and leading to cellular death.
Objectives: This study was designed to investigate the potential of L-CAV to enhance the toxicity of chemotherapeutic drugs in the human breast cancer cell line MCF-7, and determine the most favorable drug combination to exert synergistic interaction in the presence or absence of arginine in the medium.
Methods: Combination experiment based on the median-effect principle and mass-action law was conducted using constant ratios of cytotoxic agents as developed by Chou (2006).
Results: We observed that L-CAV enhanced the toxicity of cisplatin (CIS) and vinblastine (VIN) in MCF-7, even in the presence of L-ARG. On the other hand, L-CAV potentiated the toxicity of doxorubicin (DOX), paclitaxel (PTX), 5- fluoruracil (5-FU), and amphotericin-B (AMP-B) in cells grown in arginine deprived media.
Conclusion: We conclude that the combination of L-CAV with CIS or VIN can potentiate the toxicity for breast cancer cells. Thus this report presents a new possibility for treating human breast cancers known to be resistant to arginine deprivation. This initial study requires further investigation in in vivo experiments and exploration of the molecular mechanism of cellular response in human breast cancer.
Keywords: Breast cancer cells, L-canavanine, L-arginine, argininosuccinate synthase, chemotherapeutic drugs, combination.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:L-Canavanine Potentiates Cytotoxicity of Chemotherapeutic Drugs in Human Breast Cancer Cells
Volume: 17 Issue: 2
Author(s): Agustina D.R. Nurcahyanti and Michael Wink
Affiliation:
Keywords: Breast cancer cells, L-canavanine, L-arginine, argininosuccinate synthase, chemotherapeutic drugs, combination.
Abstract: Background: Due to the high level of argininosuccinate synthase (ASS), a key enzyme for the formation of arginine from citrulline, human breast cancers are often resistant to arginine deprivation therapy. An antimetabolite, Lcanavanine (L-CAV), can be incorporated into proteins in the place of arginine, disturbing protein conformation and leading to cellular death.
Objectives: This study was designed to investigate the potential of L-CAV to enhance the toxicity of chemotherapeutic drugs in the human breast cancer cell line MCF-7, and determine the most favorable drug combination to exert synergistic interaction in the presence or absence of arginine in the medium.
Methods: Combination experiment based on the median-effect principle and mass-action law was conducted using constant ratios of cytotoxic agents as developed by Chou (2006).
Results: We observed that L-CAV enhanced the toxicity of cisplatin (CIS) and vinblastine (VIN) in MCF-7, even in the presence of L-ARG. On the other hand, L-CAV potentiated the toxicity of doxorubicin (DOX), paclitaxel (PTX), 5- fluoruracil (5-FU), and amphotericin-B (AMP-B) in cells grown in arginine deprived media.
Conclusion: We conclude that the combination of L-CAV with CIS or VIN can potentiate the toxicity for breast cancer cells. Thus this report presents a new possibility for treating human breast cancers known to be resistant to arginine deprivation. This initial study requires further investigation in in vivo experiments and exploration of the molecular mechanism of cellular response in human breast cancer.
Export Options
About this article
Cite this article as:
Nurcahyanti D.R. Agustina and Wink Michael, L-Canavanine Potentiates Cytotoxicity of Chemotherapeutic Drugs in Human Breast Cancer Cells, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (2) . https://dx.doi.org/10.2174/1871520616666160223111551
DOI https://dx.doi.org/10.2174/1871520616666160223111551 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Post-Transcriptional and Post-translational Regulation of Central Carbon Metabolic Enzymes in Cancer
Anti-Cancer Agents in Medicinal Chemistry MicroRNA Targeting as a Therapeutic Strategy Against Glioma
Current Molecular Medicine Psychosocial Stress, Emotions and Cytokine-Related Disorders
Recent Patents on Inflammation & Allergy Drug Discovery pH-Sensitive Polymeric Micelles for Programmable Drug and Gene Delivery
Current Pharmaceutical Design Mevalonate Kinase Deficiency: Disclosing the Role of Mevalonate Pathway Modulation in Inflammation
Current Pharmaceutical Design Applications of Aptamers in Targeted Imaging: State of the Art
Current Topics in Medicinal Chemistry Anti-Cancer Compounds Targeted to VDAC: Potential and Perspectives
Current Medicinal Chemistry Preclinical and Clinical Efficacy of the Bisphosphonate Ibandronate in Cancer Treatment
Current Clinical Pharmacology Monoclonal Antibody “Gold Rush”
Current Medicinal Chemistry Recent Advances in pH-Sensitive Polymeric Nanoparticles for Smart Drug Delivery in Cancer Therapy
Current Drug Targets Therapeutic Potential of microRNA Against Th2-associated Immune Disorders
Current Topics in Medicinal Chemistry Clinical, Molecular- and Cytogenetic Analysis of a Case of Severe Radio- Sensitivity
Current Genomics GPR40 Carboxylic Acid Receptor Family and Diabetes: A New Drug Target
Current Drug Targets Different Targeting Strategies for Treating Breast Cancer Bone Metastases
Current Pharmaceutical Design Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?
Current Vascular Pharmacology Glycoconjugates As Vaccines for Cancer Immunotherapy: Clinical Trials and Future Directions
Anti-Cancer Agents in Medicinal Chemistry Unconventional Players on the Striated Muscle Field: microRNAs, Signaling Pathways and Epigenetic Regulators
Current Stem Cell Research & Therapy Anti-cancer and Other Bioactivities of Korean Angelica gigas Nakai (AGN) and Its Major Pyranocoumarin Compounds
Anti-Cancer Agents in Medicinal Chemistry The Potential Clinical Impact of Probiotic Treatment for the Prevention and/or Anti-Inflammatory Therapeutic Effect Against Radiation Induced Intestinal Mucositis. A Review
Recent Patents on Inflammation & Allergy Drug Discovery Extensive Phytochemistry, Comprehensive Traditional Uses, and Critical Pharmacological Profile of the Great Mullein: Verbascum thapsus L
The Natural Products Journal